Le Lézard
Classified in: Science and technology
Subject: SHA

Hexagon President and CEO Paolo Guglielmini buys 1 million Hexagon shares


STOCKHOLM, Aug. 2, 2023 /PRNewswire/ -- Hexagon's President and CEO Paolo Guglielmini today bought 1 million Hexagon shares at the price of 101 SEK, amounting to a value of 101 million SEK. With these new purchases, Paolo Guglielmini has increased his shareholding by 1,617 per cent to 1,061,827 number of shares. The shares were purchased from Melker Schörling AB.

For further information, please contact:
Tom Hull, Head of Investor Relations, Hexagon AB, +44 7442 678 437, [email protected]
Anton Heikenström, Investor Relations Manager, Hexagon AB, +46 8 601 26 26, [email protected]

The following files are available for download:

https://mb.cision.com/Main/387/3812432/2212197.pdf

Hexagon President and CEO Paolo Guglielmini buys Hexagon shares

 

SOURCE Hexagon


These press releases may also interest you

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: